Skip to main content
Premium Trial:

Request an Annual Quote

Waters to Repatriate $500M in Foreign Sales After New Law Provides Opening

NEW YORK, July 13 (GenomeWeb News) - Waters said it will take advantage of changes in federal tax laws and repatriate around $500 million in foreign earnings.

The step, which Waters said it will take in the third quarter, will force the company to pay between $22 million and $28 million federal, state, and foreign taxes.


According to a Waters SEC filing today, the new law allows companies to repatriate foreign subsidiary earnings at an effective rate of 5.25 percent -- instead of 35 percent -- before foreign tax credits.

This is significant because Waters said first-quarter sales to the global pharma market were slower than expected.

"Legislation was passed during the fourth quarter of 2004 that provided an elective 85 percent dividends received deduction which permits US corporations to repatriate earnings of foreign subsidiaries at an effective federal tax rate of 5.25 percent versus 35 percent before consideration of foreign tax credits," Waters said in its filing.


The company went on to say that on July 12 its board "adopted resolutions to repatriate approximately $500 million as a qualified distribution in accordance with the legislation."

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.